Skip to content
Operation Infinite Justice – Lifestyle
Author:
Korro Bio, Inc.
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2026
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
October 5, 2026
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2026
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 14, 2026
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 6, 2026
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
Korro to Present at the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 19, 2026
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2026
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026
1
2
Next Page
→